- Record: found
- Abstract: found
- Article: not found
Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes.
Steven E Lipshultz
1 ,
Tracie L Miller ,
Rebecca E Scully ,
Stuart R Lipsitz ,
Nader Rifai ,
Lewis B Silverman ,
Steven D Colan ,
Donna S Neuberg ,
Suzanne E Dahlberg ,
Jacqueline M Henkel ,
Barbara L Asselin ,
Uma H Athale ,
Luis A Clavell ,
Caroline Laverdière ,
Bruno Michon ,
Marshall A Schorin ,
Stephen E Sallan
Apr 01 2012
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Doxorubicin causes cardiac injury and cardiomyopathy in children with acute lymphoblastic leukemia (ALL). Measuring biomarkers during therapy might help individualize treatment by immediately identifying cardiac injury and cardiomyopathy.